554 results on '"Allegri, M"'
Search Results
2. N-Acetylcysteine Antagonizes NGF Activation of TrkA through Disulfide Bridge Interaction, an Effect Which May Contribute to Its Analgesic Activity
- Author
-
Govoni, S, Fantucci, P, Marchesi, N, Vertemara, J, Pascale, A, Allegri, M, Calvillo, L, Vanoli, E, Govoni S., Fantucci P., Marchesi N., Vertemara J., Pascale A., Allegri M., Calvillo L., Vanoli E., Govoni, S, Fantucci, P, Marchesi, N, Vertemara, J, Pascale, A, Allegri, M, Calvillo, L, Vanoli, E, Govoni S., Fantucci P., Marchesi N., Vertemara J., Pascale A., Allegri M., Calvillo L., and Vanoli E.
- Abstract
N-acetylcysteine (NAC), a mucolytic agent and an antidote to acetaminophen intoxication, has been studied in experimental conditions and trials exploring its analgesic activity based on its antioxidant and anti-inflammatory properties. The purpose of this study is to investigate additional mechanisms, namely, the inhibition of nerve growth factor (NGF) and the activation of the Tropomyosin receptor kinase A (TrkA) receptor, which is responsible for nociception. In silico studies were conducted to evaluate dithiothreitol and NAC’s interaction with TrkA. We also measured the autophosphorylation of TrkA in SH-SY5Y cells via ELISA to assess NAC’s in vitro activity against NGF-induced TrkA activation. The in silico and in vitro tests show that NAC interferes with NGF-induced TrkA activation. In particular, NAC breaks the disulfide-bound Cys 300–345 of TrkA, perturbing the NGF-TrkA interaction and producing a rearrangement of the binding site, inducing a consequent loss of their molecular recognition and spatial reorganization, which are necessary for the induction of the autophosphorylation process. The latter was inhibited by 40% using 20 mM NAC. These findings suggest that NAC could have a role as a TrkA antagonist, an action that may contribute to the activity and use of NAC in various pain states (acute, chronic, nociplastic) sustained by NGF hyperactivity and/or accompanied by spinal cord sensitization.
- Published
- 2024
3. Knowledge of COVID-19 and the impact on indigents’ access to healthcare in Burkina Faso
- Author
-
Bonnet, E., Beaugé, Y., Ba, M. F., Sidibé, S., De Allegri, M., and Ridde, V.
- Published
- 2022
- Full Text
- View/download PDF
4. How far is mixed methods research in the field of health policy and systems in Africa? A scoping review
- Author
-
De Allegri, M, Sieleunou, I, Abiiro, GA, and Ridde, V
- Published
- 2018
5. In vitro and in vivo quantification of chloroprocaine release from an implantable device in a piglet postoperative pain model
- Author
-
De Gregori S, De Gregori M, Bloise N, Bugada D, Molinaro M, Filisetti C, Allegri M, Schatman ME, and Cobianchi L
- Subjects
Postoperative pain ,hydrogel device ,chloroprocaine ,ACBA ,pharmacokinetics ,Medicine (General) ,R5-920 - Abstract
Simona De Gregori,1 Manuela De Gregori,1–4 Nora Bloise,5,6 Dario Bugada,3,4,7 Mariadelfina Molinaro,1 Claudia Filisetti,8 Massimo Allegri,3,9 Michael E Schatman,3,10,11 Lorenzo Cobianchi12,13 1Clinical and Experimental Pharmacokinetics Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; 2Pain Therapy Service, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; 3Study in Multidisciplinary Pain Research Group, Parma, Italy; 4Young Against Pain Group, Parma, Italy; 5Department of Molecular Medicine, Centre for Health Technologies, INSTM UdR of Pavia, University of Pavia, Pavia, Italy; 6Department of Occupational Medicine, Toxicology and Environmental Risks, Istituti Clinici Scientifici Maugeri, IRCCS, Lab of Nanotechnology, Pavia, Italy; 7Emergency and Intensive Care Department – ASST Papa Giovanni XXIII, Bergamo, Italy; 8“V. Buzzi” Children Hospital, Pediatric Surgery, Milan, Italy; 9Anesthesia and Intensive Care Service, IRCCS MultiMedica Hospital, Sesto San Giovanni, Milano, Italy; 10Research and Network Development, Boston Pain Care, Waltham, MA, USA; 11Department of Public Health and Community Medicine, Tufts University School of Medicine, Boston, MA, USA; 12General Surgery Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; 13Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy Background: The pharmacokinetic properties and clinical advantages of the local anesthetic chloroprocaine are well known. Here, we studied the pharmacokinetic profile of a new hydrogel device loaded with chloroprocaine to investigate the potential advantages of this new strategy for postoperative pain (POP) relief. Materials and methods: We performed both in vitro and in vivo analyses by considering plasma samples of four piglets receiving slow-release chloroprocaine. To quantify chloroprocaine and its inactive metabolite 4-amino-2-chlorobenzoic acid (ACBA), a HPLC–tandem mass spectrometry (HPLC-MS/MS) analytical method was used. Serial blood samples were collected over 108 hours, according to the exposure time to the device. Results: Chloroprocaine was consistently found to be below the lower limit of quantification, even though a well-defined peak was observed in every chromatogram at an unexpected retention time. Concerning ACBA, we found detectable plasma concentrations between T0 and T12h, with a maximum plasma concentration (Cmax) observed 3 hours after the device application. In the in vitro analyses, the nanogel remained in contact with plasma at 37°C for 90 minutes, 3 hours, 1 day, and 7 days. Chloroprocaine Cmax was identified 1 day following exposure and Cmin after 7 days, respectively. Additionally, ACBA reached the Cmax following 7 days of exposure. Conclusion: A thorough review of the literature indicates that this is the first study analyzing both in vivo and in vitro pharmacokinetic profiles of a chloroprocaine hydrogel device and is considered as a pilot study on the feasibility of including this approach to the management of POP. Keywords: postoperative outcome, hydrogel device, chloroprocaine, ACBA, pharmacokinetics
- Published
- 2018
6. Nanosilver: An innovative paradigm to promote its safe and active use
- Author
-
Gardini, D., Blosi, M., Ortelli, S., Delpivo, C., Bussolati, O., Bianchi, M.G., Allegri, M., Bergamaschi, E., and Costa, A.L.
- Published
- 2018
- Full Text
- View/download PDF
7. CYP2D6 genotype can help to predict effectiveness and safety during opioid treatment for chronic low back pain: results from a retrospective study in an Italian cohort
- Author
-
Dagostino C, Allegri M, Napolioni V, D'Agnelli S, Bignami E, Mutti A, and van Schaik RHN
- Subjects
Cytochrome P450 2D6 ,pharmacogenetics ,codeine ,oxycodone ,CLBP ,personalized medicine ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Concetta Dagostino,1,2 Massimo Allegri,2–4 Valerio Napolioni,5 Simona D’Agnelli,1 Elena Bignami,1 Antonio Mutti,1 Ron HN van Schaik6 1Department of Medicine and Surgery, University of Parma, Parma 43126, Italy; 2Study In Multidisciplinary Pain Research (SIMPAR), Milan 20100, Italy; 3Anesthesia and Intensive Care Department, IRCCS Multi Medica Hospital, Milan 20099, Italy; 4Italian Pain Institute, Milan 20100, Italy; 5Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA 94305, USA; 6Department of Clinical Chemistry, Erasmus MC, 3000 Rotterdam, The Netherlands Background: Opioids are widely used for chronic low back pain (CLBP); however, it is still unclear how to predict their effectiveness and safety. Codeine, tramadol and oxycodone are metabolized by CYP/CYP450 2D6 (CYP2D6), a highly polymorphic enzyme linked to allele-specific related differences in metabolic activity.Purpose: CYP2D6 genetic polymorphisms could potentially help to predict the effectiveness and safety of opioid-based drugs in clinical practice, especially in the treatment of CLBP.Patients and methods: A cohort of 224 Italian patients with CLBP treated with codeine or oxycodone was retrospectively evaluated to determine whether adverse reactions and effectiveness were related to CYP2D6 single-nucleotide polymorphisms. CYP2D6 genotyping was performed using the xTAG® CYP2D6 Kit v3 (Luminex) to determine CYP2D6 metabolizer phenotype (poor, intermediate, rapid and ultrarapid). Subjects from the cohort were categorized into two groups according to the occurrence of side effects (Case) or benefit (Control) after chronic analgesic treatment. The impact of CYP2D6 polymorphism on treatment outcome was tested at the metabolizer phenotype, diplotype and haplotype levels.Results: CYP2D6 polymorphism was significantly associated with opioid treatment outcome (Omnibus P=0.018, for both global haplotype and diplotype distribution test). CYP2D6*6 and *9 carriers, alleles characterized by a reduced (*9) or absent (*6) enzymatic activity, were significantly (P
- Published
- 2018
8. Second edition of SIMPAR’s “Feed Your Destiny” workshop: the role of lifestyle in improving pain management
- Author
-
De Gregori M, Belfer I, De Giorgio R, Marchesini M, Muscoli C, Rondanelli M, Martini D, Mena P, Arranz LI, Lorente-Cebrián S, Perna S, Villarini A, Salamone M, Allegri M, and Schatman ME
- Subjects
Chronic pain ,multidisciplinary pain management ,personalized nutrition ,nutritional supplements. ,Medicine (General) ,R5-920 - Abstract
Manuela De Gregori,1–3 Inna Belfer,2,4 Roberto De Giorgio,5 Maurizio Marchesini,2,3,6 Carolina Muscoli,7 Mariangela Rondanelli,2,8 Daniela Martini,9 Pedro Mena,9 Laura Isabel Arranz,2,10 Silvia Lorente-Cebrián,2,11 Simone Perna,8 Anna Villarini,12 Maurizio Salamone,2,13,14 Massimo Allegri,2,15 Michael E Schatman2,16,17 1 Pain Therapy Service, Fondazione IRCCS Polclinico San Matteo, Pavia, Italy; 2Study in Multidisciplinary Pain Research Group, Parma, Italy; 3Young Against Pain Group, Parma, Italy; 4Faculty of Dentistry, McGill University, Montreal, QC, Canada; 5Department of Clinical Sciences, Nuovo Arcispedale S. Anna, University of Ferrara, Ferrara, Italy; 6Anesthesia, Intensive Care and Pain Therapy Service, Azienda Ospedaliero, Universitaria of Parma, Parma, Italy; 7Department of Health Sciences, Institute of Research for Food Safety and Health, University “Magna Graecia” of Catanzaro, Parma, Italy; 8Department of Public Health, Section of Human Nutrition and Dietetics, Azienda di Servizi alla Persona di Pavia, University of Pavia, Pavia, Italy; 9Human Nutrition Unit, Department of Food & Drugs, University of Parma, Parma, Italy; 10Department of Nutrition, Food Sciences and Gastronomy, University of Barcelona, Barcelona, Spain; 11Department of Nutrition, Food Science and Physiology, Faculty of Pharmacy, Center for Nutrition Research, University of Navarra, Pamplona, Spain; 12Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 13Science department, Metagenics Italia srl, Milano, Italy; 14Società internazionale di Neuropsicocardiologia, Trapani, Italy; 15Anesthesia and Intensive Care Service – IRCCS MultiMedica Hospital, Sesto San Giovanni, Milano, Italy; 16Research and Network Development, Boston Pain Care, Waltham, MA, USA; 17Department of Public Health and Community Medicine, Tufts University School of Medicine, Boston, MA, USA Abstract: This review is aimed to summarize the latest data regarding pain and nutrition, which have emerged during the second edition of Feed Your Destiny (FYD). Theme presentations and interactive discussions were held at a workshop on March 30, 2017, in Florence, Italy, during the 9th Annual Meeting of Study in Multidisciplinary Pain Research, where an international faculty, including recognized experts in nutrition and pain, reported the scientific evidence on this topic from various perspectives. Presentations were divided into two sections. In the initial sessions, we analyzed the outcome variables and methods of measurement for health claims pertaining to pain proposed under Regulation EC No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health claims made on foods. Moreover, we evaluated how the Mediterranean diet can have a potential impact on pain, gastrointestinal disorders, obesity, cancer, and aging. Second, we discussed the evidence regarding vitamin D as a nutraceutical that may contribute to pain control, evaluating the interindividual variability of pain nature and nurture, and the role of micro-RNAs (miRNAs), polyunsaturated omega 3 fatty acids, and phenolic compounds, with a final revision of the clinical role of nutrition in tailoring pain therapy. The key take-home message provided by the FYD workshop was that a balanced, personalized nutritional regimen might play a role as a synergic strategy that can improve management of chronic pain through a precision medicine approach. Keywords: chronic pain, multidisciplinary pain management, personalized nutrition, nutritional supplements
- Published
- 2018
9. Immune function after major surgical interventions: the effect of postoperative pain treatment
- Author
-
Amodeo G, Bugada D, Franchi S, Moschetti G, Grimaldi S, Panerai A, Allegri M, and Sacerdote P
- Subjects
opioids ,postoperative pain ,cytokines ,immunomodulation ,lymphoproliferation ,surgery ,Medicine (General) ,R5-920 - Abstract
Giada Amodeo,1 Dario Bugada,2–4 Silvia Franchi,1 Giorgia Moschetti,1 Stefania Grimaldi,5 Alberto Panerai,1 Massimo Allegri,2 Paola Sacerdote1 1Department of Pharmacological and Biomolecular Sciences, University of Milano, Milano, Italy; 2Study In Multidisciplinary Pain Research Group, 3Department of Anesthesia and ICU, ASST Papa Giovanni XXIII, Bergamo, Italy; 4Department of Anesthesia and ICU, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; 5Department of Anesthesia, IRCCS Humanitas Research Center, Rozzano, Italy Introduction: Impaired immune function during the perioperative period may be associated with worse short- and long-term outcomes. Morphine is considered a major contributor to immune modulation. Patients and methods: We performed a pilot study to investigate postoperative immune function by analyzing peripheral blood mononuclear cells’ functionality and cytokine production in 16 patients undergoing major abdominal surgery. All patients were treated with intravenous (i.v.) patient-controlled analgesia with morphine and continuous wound infusion with ropivacaine+methylprednisolone for 24 hours. After 24 hours, patients were randomized into two groups, one continuing intrawound infusion and the other receiving only i.v. analgesia. We evaluated lymphoproliferation and cytokine production by peripheral blood mononuclear cells at the end of surgery and at 24 and 48 hours postoperatively. Results: A significant reduction in TNF-α, IL-2, IFN-γ and lymphoproliferation was observed immediately after surgery, indicating impaired cell-mediated immunity. TNF-α and IFN-γ remained suppressed up to 48 hours after surgery, while a trend to normalization was observed for IL-2 and lymphoproliferation, irrespective of the treatment group. A significant inverse correlation was present between age and morphine and between age and lymphoproliferation. No negative correlation was present between morphine and cytokine production. We did not find any differences within the two groups between 24 and 48 hours in terms of morphine consumption and immune responses. Conclusion: A relevant depression of cell-mediated immunity is associated with major surgery and persists despite optimal analgesia. Even though morphine may participate in immunosuppression, we did not retrieve any dose-related effect. Keywords: opioids, postoperative pain, cytokines, immunomodulation, lymphoproliferation, surgery
- Published
- 2018
10. From SIMPAR to CIMPARC: the evolution of international pain research and management
- Author
-
Allegri M, Ingelmo PM, and Schatman ME
- Subjects
Acute and chronic pain ,SIMPAR ,CIMPARC ,Medicine (General) ,R5-920 - Abstract
Massimo Allegri,1–3 Pablo M Ingelmo,1,4–7 Michael E Schatman1,8,9 1Consortium of Multidisciplinary Pain Researchers and Clinicians (CIMPARC) Group, Milan, Italy; 2Pain Therapy Service, Policlinico Monza Hospital, Monza, Italy; 3Italian Pain Group, Milan, Italy; 4Department of Anesthesia, McGill University, Montreal, QC, Canada; 5Chronic Pain Service, Montreal Children’s Hospital, Montreal, QC, Canada; 6Shriners Hospital for Children, Montreal, QC, Canada; 7Alan Edwards Centre for Research on Pain, Montreal, QC, Canada; 8Research and Network Development, Boston Pain Care, Waltham, MA, USA; 9Department of Public Health and Community Medicine, Tufts University School of Medicine, Boston, MA, USA
- Published
- 2018
11. Continuous wound infusion with chloroprocaine in a pig model of surgical lesion: drug absorption and effects on inflammatory response
- Author
-
Allegri M, Bugada D, De Gregori M, Avanzini MA, De Silvestri A, Petroni A, Sala A, Filisetti C, Icaro Cornaglia A, and Cobianchi L
- Subjects
Continuous wound infusion ,pig model ,chloroprocaine ,pharmacokinetics ,inflammation ,postoperative pain ,Medicine (General) ,R5-920 - Abstract
Massimo Allegri,1,2 Dario Bugada,1–3 Manuela De Gregori,2,4 Maria A Avanzini,5 Annalisa De Silvestri,6 Anna Petroni,7 Angelo Sala,7,8 Claudia Filisetti,9–11 Antonia Icaro Cornaglia,12 Lorenzo Cobianchi13,14 1Department of Medicine and Surgery, University of Parma, Parma 2SIMPAR Group (Study in Multidisciplinary PAin Research), 3Department of Anaesthesia and ICU, ASST Papa Giovanni XXIII, Bergamo, 4Pain Therapy Service, Fondazione IRCCS Policlinico San Matteo, 5Laboratory of Transplant Immunology/Cell Factory, IRCCS Foundation Policlinico San Matteo, 6Clinical epidemiology and Biometrics Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, 7Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, 8I.B.I.M., C.N.R., Palermo, 9PhD School, University of Pavia, 10Department of Pediatric Surgery, Fondazione IRCCS Policlinico San Matteo, Pavia, 11Department of Pediatric Surgery, “V. Buzzi” Children’s Hospital, Milan, 12Department of Public Health, Experimental and Forensic Medicine, University of Pavia, 13Department of Surgical, Clinical, Paediatric and Diagnostic Science, University of Pavia, 14General Surgery 1, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy Abstract: Continuous wound infusion (CWI) may protect from inflammation, hyperalgesia and persistent pain. Current local anesthetics display suboptimal pharmacokinetic profile during CWI; chloroprocaine (CP) has ideal characteristics, but has never been tested for CWI. We performed an animal study to investigate the pharmacokinetic profile and anti-inflammatory effect of CP during CWI. A total of 14 piglets received an infusion catheter after pararectal laparotomy and were randomly allocated to one of three groups: 5 mL/h infusion of saline (group A), CP 1.5% (group B) and CP 0.5% (group C). Blood sampling was performed to assess absorption and systemic inflammation at 0, 3, 6, 12, 24, 48, 72, 96, 102 and 108 hours. The wound and contralateral healthy abdominal wall were sampled for histological analyses. Absorption of CP from the site of infusion, evaluated as the plasmatic concentrations of CP and its metabolite, 4-amino-2-chlorobenzoic acid (CABA), showed a peak during the first 6 hours, but both CP and its metabolite rapidly disappeared after stopping CP infusion. Local inflammation was reduced in groups B and C (CP-treated p < 0.001), in a CP dose-dependent fashion. While CP inhibited in a dose-dependent manner pig mononuclear cells (MNCs) in vitro proliferation to a polyclonal activator, no effect on systemic cytokines’ concentrations or on ex vivo monocytes’ responsiveness was observed, suggesting the lack of systemic effects, in line with the very short half-life of CP in plasma. CP showed a very good profile for use in CWI, with dose-dependent local anti-inflammatory effects, limited absorption and rapid clearance from the bloodstream upon discontinuation. No cytotoxicity or side effects were observed. CP, therefore, may represent an optimal choice for clinical CWI, adaptable to each patient’s need, and protective on wound inflammatory response (and hyperalgesia) after surgery. Keywords: continuous wound infusion, pig model, chloroprocaine, pharmacokinetics, inflammation, postoperative pain
- Published
- 2017
12. Cannabis and intractable chronic pain: an explorative retrospective analysis of Italian cohort of 614 patients
- Author
-
Fanelli G, De Carolis G, Leonardi C, Longobardi A, Sarli E, Allegri M, and Schatman ME
- Subjects
Cannabis ,Cannabinoids ,Chronic pain ,safety ,cannabidiol ,Medicine (General) ,R5-920 - Abstract
Guido Fanelli,1,2 Giuliano De Carolis,3 Claudio Leonardi,4 Adele Longobardi,5,6 Ennio Sarli,7,8 Massimo Allegri,1,2 Michael E Schatman9 1Anesthesia, Critical Care and Pain Medicine Unit, Division of Surgical Sciences, Department of Medicine and Surgery, University of Parma, 2Anesthesia, Intensive Care and Pain Therapy Service, Azienda Ospedaliero Universitaria Parma, Parma, 3Pain Therapy Service, Azienda Ospedaliero Universitaria Pisana, Pisa, 4Department of Drug Addiction Diseases, Local Public Health of Rome, Rome, 5Department of Neurosciences, Reproductive and Odontostomatological Sciences, University of Naples “Federico II”, Naples, 6Young Against the Pain (YAP) Group, Parma, 7Progetti Live Surgery, 8PinHub Group, Florence, Italy; 9Department of Public Health and Community Medicine, Tufts University School of Medicine, Boston, MA, USA Background: Despite growing interest in the therapeutic use of cannabis to manage chronic pain, only limited data that address these issues are available. In recent years, a number of nations have introduced specific laws to allow patients to use cannabis preparations to treat a variety of medical conditions. In 2015, the Italian government authorized the use of cannabis to treat several diseases, including chronic pain generally, spasticity in multiple sclerosis, cachexia and anorexia among AIDS and cancer patients, glaucoma, Tourette syndrome, and certain types of epilepsy. We present the first snapshot of the Italian experience with cannabis use for chronic pain over the initial year of its use.Methods: This is a retrospective case series analysis of all chronic pain patients treated with oral or vaporized cannabis in six hubs during the initial year following the approval of the new Italian law (December 2015 to November 2016). We evaluated routes of administration, types of cannabis products utilized, dosing, and effectiveness and safety of the treatment.Results: As only one of the six centers has extensively used cannabinoids for intractable chronic pain (614 patients of 659), only the population from Azienda Ospedaliero Universitaria Pisana (Pisa) was considered. Cannabis tea was the primary mode of delivery, and in almost all cases, it was used in association with all the other pain treatments. Initial and follow-up cannabinoid concentrations were found to vary considerably. At initial follow-up, 76.2% of patients continued the treatment, and
- Published
- 2017
13. Combining pain therapy with lifestyle: the role of personalized nutrition and nutritional supplements according to the SIMPAR Feed Your Destiny approach
- Author
-
De Gregori M, Muscoli C, Schatman ME, Stallone T, Intelligente F, Rondanelli M, Franceschi F, Arranz LI, Lorente Cebrián S, Salamone M, Ilari S, Belfer I, and Allegri M
- Subjects
Pain ,personalized nutrition ,nutritional supplements ,Medicine (General) ,R5-920 - Abstract
Manuela De Gregori,1–3 Carolina Muscoli,2,4,5 Michael E Schatman,2,6 Tiziana Stallone,2,7 Fabio Intelligente,2,8 Mariangela Rondanelli,2,9 Francesco Franceschi,2,10 Laura Isabel Arranz,2,11 Silvia Lorente-Cebrián,2,12 Maurizio Salamone,2,13,14 Sara Ilari,2,5 Inna Belfer,2,15 Massimo Allegri2,16,17 1Pain Therapy Service, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; 2Study in Multidisciplinary Pain Research Group, 3Young Against Pain Group, Parma, Italy; 4Department of Health Sciences, Institute of Research for Food Safety and Health, University “Magna Graecia” of Catanzaro, Parma, Italy; 5IRCCS San Raffaele Pisana, Roccelletta di Borgia, Catanzaro, Italy; 6US Pain Foundation, Bellevue, WA, USA; 7ENPAB, Rome, 8Chronic Pain Service Anestesia Day-Surgery, IRCCS Humanitas Research Hospital, Rozzano, 9Department of Public Health, Section of Human Nutrition and Dietetics, Azienda di Servizi alla Persona di Pavia, University of Pavia, Pavia, 10Institute of Internal Medicine, Catholic University of Rome, Rome, Italy; 11Department of Nutrition, Food Sciences and Gastronomy, University of Barcelona, Barcelona, 12Department of Nutrition, Food Science and Physiology, Center for Nutrition Research, University of Navarra, Pamplona, Spain; 13Metagenics Italia srl, Milano, 14Italian Lifestyle Medicine Association, Bari, Italy; 15Faculty of Dentistry, McGill University, Montreal, QC, Canada; 16Department of Surgical Sciences, University of Parma, 17Anesthesia, Intensive Care and Pain Therapy Service, Azienda Ospedaliero, Universitaria of Parma, Parma, Italy Abstract: Recently, attention to the lifestyle of patients has been rapidly increasing in the field of pain therapy, particularly with regard to the role of nutrition in pain development and its management. In this review, we summarize the latest findings on the role of nutrition and nutraceuticals, microbiome, obesity, soy, omega-3 fatty acids, and curcumin supplementation as key elements in modulating the efficacy of analgesic treatments, including opioids. These main topics were addressed during the first edition of the Study In Multidisciplinary Pain Research workshop: “FYD (Feed Your Destiny): Fighting Pain”, held on April 7, 2016, in Rome, Italy, which was sponsored by a grant from the Italian Ministry of Instruction on “Nutraceuticals and Innovative Pharmacology”. The take-home message of this workshop was the recognition that patients with chronic pain should undergo nutritional assessment and counseling, which should be initiated at the onset of treatment. Some foods and supplements used in personalized treatment will likely improve clinical outcomes of analgesic therapy and result in considerable improvement of patient compliance and quality of life. From our current perspective, the potential benefit of including nutrition in personalizing pain medicine is formidable and highly promising. Keywords: pain, personalized nutrition, nutritional supplements
- Published
- 2016
14. Electrical Nerve Stimulation and Percutaneous Identification of the Target
- Author
-
Perotti, L., Allegri, M., Matteazzi, A., Grossi, P., Alemanno, Fernando, editor, Bosco, Mario, editor, and Barbati, Aldo, editor
- Published
- 2014
- Full Text
- View/download PDF
15. The genesis of the PM-JAY health insurance scheme in India: technical and political elements influencing a national reform towards universal health coverage.
- Author
-
Srivastava, S, Bertone, M P, Parmar, D, Walsh, C, and Allegri, M De
- Subjects
HEALTH insurance ,REFORMS ,MIDDLE-income countries ,GOVERNMENT agencies ,BRANDING (Marketing) - Abstract
Many countries are using health insurance to advance progress towards universal health coverage (UHC). India launched the Pradhan Mantri Jan Arogya Yojana (PM-JAY) health insurance scheme in 2018. We examine the political economy context around PM-JAY policy formulation, by examining the perspectives of policy stakeholders shaping decisions around the reform. More specifically, we focus on early policy design at the central (national) level. We use a framework on the politics of UHC reform proposed by Fox and Reich (The politics of universal health coverage in low- and middle-income countries: A framework for evaluation and action. J. Health Polit. Policy Law 2015; 40 :1023–1060), to categorize the reform into phases and examine the interactions between actors, institutions, interests, ideas and ideology which shaped reform decisions. We interviewed 15 respondents in Delhi between February and April 2019, who were either closely associated with the reform process or subject experts. The ruling centre-right government introduced PM-JAY shortly before national elections, drawing upon policy legacies from prior and state insurance schemes. Empowered policy entrepreneurs within the government focused discourse around ideas of UHC and strategic purchasing, and engaged in institution building leading to the creation of the National Health Authority and State Health Agencies through policy directives, thereby expanding state infrastructural and institutional power for insurance implementation. Indian state inputs were incorporated in scheme design features like mode of implementation, benefit package and provider network, while features like the coverage amount, portability of benefits and branding strategy were more centrally driven. These balanced negotiations opened up political space for a cohesive, central narrative of the reform and facilitated adoption. Our analysis shows that the PM-JAY reform focused on bureaucratic rather than ideological elements and that technical compromises and adjustments accommodating the interests of states enabled the political success of policy formulation. Appreciating these politics, power and structural issues shaping PM-JAY institutional design will be important to understand how PM-JAY is implemented and how it advances UHC in India. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
16. From micro- to nanostructured implantable device for local anesthetic delivery
- Author
-
Zorzetto L, Brambilla P, Marcello E, Bloise N, De Gregori M, Cobianchi L, Peloso A, Allegri M, Visai L, and Petrini P
- Subjects
Local anesthetics ,drug delivery systems ,micro-structured materials ,nano-structured materials ,nano-structured implantable devices ,Medicine (General) ,R5-920 - Abstract
Laura Zorzetto,1 Paola Brambilla,1 Elena Marcello,1 Nora Bloise,2 Manuela De Gregori,3 Lorenzo Cobianchi,4,5 Andrea Peloso,4,5 Massimo Allegri,6 Livia Visai,2,7 Paola Petrini1 1Department of Chemistry, Materials and Chemical Engineering ‘G. Natta’, Politecnico di Milano, Milan, 2Department of Molecular Medicine, Centre for Health Technologies (CHT), INSTM UdR of Pavia, University of Pavia, 3Pain Therapy Service, IRCCS Foundation Policlinico San Matteo Pavia, Pavia, 4General Surgery Department, IRCCS Foundation Policlinico San Matteo, Pavia, 5Departments of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, 6Department of Surgical Sciences, University of Parma, Parma, 7Department of Occupational Medicine, Toxicology and Environmental Risks, S. Maugeri Foundation, IRCCS, Lab of Nanotechnology, Pavia, Italy Abstract: Local anesthetics block the transmission of painful stimuli to the brain by acting on ion channels of nociceptor fibers, and find application in the management of acute and chronic pain. Despite the key role they play in modern medicine, their cardio and neurotoxicity (together with their short half-life) stress the need for developing implantable devices for tailored local drug release, with the aim of counterbalancing their side effects and prolonging their pharmacological activity. This review discusses the evolution of the physical forms of local anesthetic delivery systems during the past decades. Depending on the use of different biocompatible materials (degradable polyesters, thermosensitive hydrogels, and liposomes and hydrogels from natural polymers) and manufacturing processes, these systems can be classified as films or micro- or nanostructured devices. We analyze and summarize the production techniques according to this classification, focusing on their relative advantages and disadvantages. The most relevant trend reported in this work highlights the effort of moving from microstructured to nanostructured systems, with the aim of reaching a scale comparable to the biological environment. Improved intracellular penetration compared to microstructured systems, indeed, provides specific drug absorption into the targeted tissue and can lead to an enhancement of its bioavailability and retention time. Nanostructured systems are realized by the modification of existing manufacturing processes (interfacial deposition and nanoprecipitation for degradable polyester particles and high- or low-temperature homogenization for liposomes) or development of novel strategies (electrospun matrices and nanogels). The high surface-to-volume ratio that characterizes nanostructured devices often leads to a burst drug release. This drawback needs to be addressed to fully exploit the advantage of the interaction between the target tissues and the drug: possible strategies could involve specific binding between the drug and the material chosen for the device, and a multiscale approach to reach a tailored, prolonged drug release. Keywords: pain management, microparticle, microencapsulation, nanoparticle production, nanogels, liposomes
- Published
- 2016
17. Does a research group increase impact on the scientific community or general public discussion? Alternative metric-based evaluation
- Author
-
De Gregori M, Scotti V, De Silvestri A, Curti M, Fanelli G, Allegri M, and Schatman ME
- Subjects
Altmetrics ,SIMPAR group ,pain research impact ,Medicine (General) ,R5-920 - Abstract
Manuela De Gregori,1-3,* Valeria Scotti,4,* Annalisa De Silvestri,4 Moreno Curti,4 Guido Fanelli,2,5,6 Massimo Allegri,2,5,6 Michael E Schatman,2,7 1Pain Therapy Service, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; 2Study In Multidisciplinary PAin Research Group, Parma, Italy; 3Young Against Pain Group, Parma, Italy; 4Center for Scientific Documentation and Biometry Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; 5Anesthesia, Critical Care, and Pain Medicine, Department of Surgical Sciences, University of Parma, Italy; 6Anesthesia, Intensive Care and Pain Therapy Service, Azienda Ospedaliero, Universitaria di Parma, Parma, Italy; 7US Pain Foundation, Bellevue, WA, USA *These authors contributed equally to this work. Abstract: In this study, we investigated the impact of scientific publications of the Italian SIMPAR (Study In Multidisciplinary PAin Research) group by using altmetrics, defined as nontraditional metrics constituting an alternative to more traditional citation-impact metrics, such as impact factor and H-index. By correlating traditional and alternative metrics, we attempted to verify whether publications by the SIMPAR group collectively had more impact than those performed by its individual members, either in solo publications or in publications coauthored by non-SIMPAR group investigators (which for the purpose of this study we will refer to as “individual publications”). For all the 12 members of the group analyzed (pain therapists, biologists, and pharmacologists), we created Open Researcher and Contributor ID and Impact Story accounts, and synchronized these data. Manually, we calculated the level metrics for each article by dividing the data obtained from the research community by those obtained from the public community. We analyzed 759 articles, 18 of which were published by the SIMPAR group. Altmetrics demonstrated that SIMPAR group publications were more likely to be saved (77.8% vs 45.9%), discussed (61.1% vs 1.1%, P
- Published
- 2016
18. The impact of user fee removal policies on household out-of-pocket spending: evidence against the inverse equity hypothesis from a population based study in Burkina Faso
- Author
-
Ridde, V., Agier, I., Jahn, A., Mueller, O., Tiendrebéogo, J., Yé, M., and De Allegri, M.
- Published
- 2015
19. Supply-side contribution to the lack of PBF impact on unmet need for family planning in Burkina Faso
- Author
-
Hertler, C, primary, Lohmann, J, additional, Koulidiati, JL, additional, Robyn, PJ, additional, Somda, SMA, additional, De Allegri, M, additional, and Brenner, S, additional
- Published
- 2022
- Full Text
- View/download PDF
20. 138 - La couverture vaccinale dans les délais recommandés et ses déterminants au Burkina Faso
- Author
-
Kaboré, R., primary, Nebié, E., additional, Sidibé, A., additional, Lohmann, J., additional, Brenner, S., additional, Badolo, H., additional, Hamadou, S., additional, Ouedraogo, N., additional, De Allegri, M., additional, and Koulidiati, J-L., additional
- Published
- 2022
- Full Text
- View/download PDF
21. 219 - Statut nutritionnel des enfants de moins de 5 ans et facteurs socioéconomiques associés. Enquête de population au Burkina Faso
- Author
-
Picbougoum, T.B., primary, Somda, S.M.A., additional, Hien, H.M., additional, De Allegri, M., additional, Méda, N., additional, and Robert, A., additional
- Published
- 2022
- Full Text
- View/download PDF
22. 5% lidocaine medicated plaster double effect in a case of orofacial localized neuropathic pain
- Author
-
Casale R, Romanenko Y, and Allegri M
- Subjects
Medicine (General) ,R5-920 - Abstract
Roberto Casale,1,2 Yuriy Romanenko,2,3 Massimo Allegri4–6 1Department of Clinical Neurophysiology and Pain Rehabilitation Unit, Foundation "Salvatore Maugeri", Research and Care Institute, IRCCS, Pavia, Italy; 2EFIC Montescano Pain School, Montescano, Italy; 3Department of Neurology, Lugansk City Hospital 4, Lugansk, Ukraine; 4Department of Clinical, Surgical, Diagnostic and Pediatric Sciences University of Pavia, Pavia, Italy; 5Pain Therapy Service Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; 6SIMPAR group, Pavia, Italy Abstract: Localized neuropathic pain (LNP) is a type of neuropathic pain that is characterized by “consistent and limited area(s) of maximum pain associated with negative or positive sensory signs and/or spontaneous symptoms characteristic of neuropathic pain”. This definition encompasses a huge number of neuropathic orofacial pain syndromes. We present a case report of a patient who was affected with sleep apnea syndrome treated with nocturnal oxygen mask delivery, in whom orofacial LNP hampered the wearing of a mask due to unbearable burning and throbbing pain. The application of 5% lidocaine medicated plaster during the night led to an impressive reduction of both the pain level and the size of the painful area due to the plaster's pharmacological mechanisms, which were associated with a secondary benefit due to its mechanical protective action. This case report shows how these two factors could be of clinical value and have to be considered more systematically in the treatment of LNP in reducing pain and the size of the painful area. Keywords: trigeminal pain, localized neuropathic pain, topical treatment, 5% lidocaine medicated plaster
- Published
- 2014
23. How do the EMA and FDA decide which anticancer drugs make it to the market? A comparative qualitative study on decision makers’ views
- Author
-
Tafuri, G., Stolk, P., Trotta, F., Putzeist, M., Leufkens, H.G., Laing, R.O., and De Allegri, M.
- Published
- 2014
- Full Text
- View/download PDF
24. Effects of Environmental Factors on Severity and Mortality of COVID-19
- Author
-
Kifer, D, Bugada, D, Villar-Garcia, J, Gudelj, I, Menni, C, Sudre, C, Vuckovic, F, Ugrina, I, Lorini, L, Posso, M, Bettinelli, S, Ughi, N, Maloberti, A, Epis, O, Giannattasio, C, Rossetti, C, Kalogjera, L, Persec, J, Ollivere, L, Ollivere, B, Yan, H, Cai, T, Aithal, G, Steves, C, Kantele, A, Kajova, M, Vapalahti, O, Sajantila, A, Wojtowicz, R, Wierzba, W, Krol, Z, Zaczynski, A, Zycinska, K, Postula, M, Luksic, I, Civljak, R, Markotic, A, Brachmann, J, Markl, A, Mahnkopf, C, Murray, B, Ourselin, S, Valdes, A, Horcajada, J, Castells, X, Pascual, J, Allegri, M, Primorac, D, Spector, T, Barrios, C, Lauc, G, Kifer D., Bugada D., Villar-Garcia J., Gudelj I., Menni C., Sudre C., Vuckovic F., Ugrina I., Lorini L. F., Posso M., Bettinelli S., Ughi N., Maloberti A., Epis O., Giannattasio C., Rossetti C., Kalogjera L., Persec J., Ollivere L., Ollivere B. J., Yan H., Cai T., Aithal G. P., Steves C. J., Kantele A., Kajova M., Vapalahti O., Sajantila A., Wojtowicz R., Wierzba W., Krol Z., Zaczynski A., Zycinska K., Postula M., Luksic I., Civljak R., Markotic A., Brachmann J., Markl A., Mahnkopf C., Murray B., Ourselin S., Valdes A. M., Horcajada J. P., Castells X., Pascual J., Allegri M., Primorac D., Spector T. D., Barrios C., Lauc G., Kifer, D, Bugada, D, Villar-Garcia, J, Gudelj, I, Menni, C, Sudre, C, Vuckovic, F, Ugrina, I, Lorini, L, Posso, M, Bettinelli, S, Ughi, N, Maloberti, A, Epis, O, Giannattasio, C, Rossetti, C, Kalogjera, L, Persec, J, Ollivere, L, Ollivere, B, Yan, H, Cai, T, Aithal, G, Steves, C, Kantele, A, Kajova, M, Vapalahti, O, Sajantila, A, Wojtowicz, R, Wierzba, W, Krol, Z, Zaczynski, A, Zycinska, K, Postula, M, Luksic, I, Civljak, R, Markotic, A, Brachmann, J, Markl, A, Mahnkopf, C, Murray, B, Ourselin, S, Valdes, A, Horcajada, J, Castells, X, Pascual, J, Allegri, M, Primorac, D, Spector, T, Barrios, C, Lauc, G, Kifer D., Bugada D., Villar-Garcia J., Gudelj I., Menni C., Sudre C., Vuckovic F., Ugrina I., Lorini L. F., Posso M., Bettinelli S., Ughi N., Maloberti A., Epis O., Giannattasio C., Rossetti C., Kalogjera L., Persec J., Ollivere L., Ollivere B. J., Yan H., Cai T., Aithal G. P., Steves C. J., Kantele A., Kajova M., Vapalahti O., Sajantila A., Wojtowicz R., Wierzba W., Krol Z., Zaczynski A., Zycinska K., Postula M., Luksic I., Civljak R., Markotic A., Brachmann J., Markl A., Mahnkopf C., Murray B., Ourselin S., Valdes A. M., Horcajada J. P., Castells X., Pascual J., Allegri M., Primorac D., Spector T. D., Barrios C., and Lauc G.
- Abstract
Background: Most respiratory viruses show pronounced seasonality, but for SARS-CoV-2, this still needs to be documented. Methods: We examined the disease progression of COVID-19 in 6,914 patients admitted to hospitals in Europe and China. In addition, we evaluated progress of disease symptoms in 37,187 individuals reporting symptoms into the COVID Symptom Study application. Findings: Meta-analysis of the mortality risk in seven European hospitals estimated odds ratios per 1-day increase in the admission date to be 0.981 (0.973–0.988, p < 0.001) and per increase in ambient temperature of 1°C to be 0.854 (0.773–0.944, p = 0.007). Statistically significant decreases of comparable magnitude in median hospital stay, probability of transfer to the intensive care unit, and need for mechanical ventilation were also observed in most, but not all hospitals. The analysis of individually reported symptoms of 37,187 individuals in the UK also showed the decrease in symptom duration and disease severity with time. Interpretation: Severity of COVID-19 in Europe decreased significantly between March and May and the seasonality of COVID-19 is the most likely explanation.
- Published
- 2021
25. Reduction of painful area as new possible therapeutic target in post-herpetic neuropathic pain treated with 5% lidocaine medicated plaster: a case series
- Author
-
Casale R, Di Matteo M, Minella CE, Fanelli G, and Allegri M
- Subjects
Medicine (General) ,R5-920 - Abstract
Roberto Casale,1,2 Maria Di Matteo,3,7 Cristina E Minella,4,7 Guido Fanelli,5,7 Massimo Allegri4,6,71Department of Clinical Neurophysiology and Pain Rehabilitation Unit, Foundation Salvatore Maugeri, IRCCS, Pavia, 2EFIC Montescano School, Montescano, 3Anesthesia and Intensive Care I, 4Pain Therapy Service, Fondazione IRCCS Policlinico San Matteo, Pavia, 5Department of Anesthesia, Intensive Care and Pain Therapy, Azienda Ospedaliera Universitaria Parma, University of Parma, Parma, 6Department of Clinical, Surgical, Diagnostic and Pediatric Science, University of Pavia, Pavia, 7Study In Multidisciplinary Pain Research Group, Parma, ItalyAbstract: Post-herpetic neuralgia (PHN) is neuropathic pain persisting after an acute episode of herpes zoster, and is associated with severe pain and sensory abnormalities that adversely affect the patient's quality of life and increase health care costs. Up to 83% of patients with PHN describe localized neuropathic pain, defined as “a type of neuropathic pain characterized by consistent and circumscribed area(s) of maximum pain”. Topical treatments have been suggested as a first-line treatment for localized neuropathic pain. Use of 5% lidocaine medicated plaster could reduce abnormal nervous peripheral discharge and via the plaster could have a “protective” function in the affected area. It has been suggested that use of this plaster could reduce pain as well as the size of the painful area. To evaluate this possible outcome, we retrospectively reviewed eight patients with PHN, treated using 5% lidocaine medicated plaster. During a follow-up period of 3 months, we observed good pain relief, which was associated with a 46% reduction in size of the painful area after one month (from 236.38±140.34 cm2 to 128.80±95.7 cm2) and a 66% reduction after 3 months (81.38±59.19 cm2). Our study cohort was composed mainly of elderly patients taking multiple drugs to treat comorbidities, who have a high risk of drug–drug interactions. Such patients benefit greatly from topical treatment of PHN. Our observations confirm the effectiveness of lidocaine plasters in the treatment of PHN, indicating that 5% lidocaine medicated plaster could reduce the size of the painful area. This last observation has to be confirmed and the mechanisms clarified in appropriate larger randomized controlled trials.Keywords: localized neuropathic pain, topical treatment, chronic pain, drug–drug interactions, patient's outcome
- Published
- 2014
26. Pain assessment in animal models: do we need further studies?
- Author
-
Gigliuto C, De Gregori M, Malafoglia V, Raffaeli W, Compagnone C, Visai L, Petrini P, Avanzini MA, Muscoli C, Viganò J, Calabrese F, Dominioni T, Allegri M, and Cobianchi L
- Subjects
Medicine (General) ,R5-920 - Abstract
Carmelo Gigliuto,1 Manuela De Gregori,2 Valentina Malafoglia,3 William Raffaeli,3 Christian Compagnone,4 Livia Visai,5,6 Paola Petrini,7 Maria Antonietta Avanzini,9 Carolina Muscoli,8 Jacopo Viganò,11 Francesco Calabrese,11 Tommaso Dominioni,11 Massimo Allegri,2,10 Lorenzo Cobianchi111Anaesthesia and Intensive Care, University of Pavia, Pavia, 2Pain Therapy Service, Fondazione IRCCS Policlinico San Matteo, Pavia, 3ISAL Foundation, Institute for Research on Pain, Torre Pedrera, Rimini, 4Department of Anaesthesia, Intensive Care and Pain Therapy, Azienda Ospedaliera Universitaria Parma, University of Parma, Parma, 5Department of Molecular Medicine, Center for Tissue Engineering (CIT), INSTM UdR of Pavia, University of Pavia, Pavia, 6Department of Occupational Medicine, Ergonomy and Disability, Laboratory of Nanotechnology, Salvatore Maugeri Foundation, IRCCS, Veruno, 7Dipartimento di Chimica, Materiali e Ingegneria Chimica 'G Natta' and Unità di Ricerca Consorzio INSTM, Politecnico di Milano, Milan, 8Department of Health Science, University Magna Grecia of Catanzaro and Centro del Farmaco, IRCCS San Raffaele Pisana, Roma, 9Laboratory of Transplant Immunology/Cell Factory, Fondazione IRCCS Policlinico "San Matteo", Pavia, 10Department of Clinical, Surgical, Diagnostic and Paediatric Sciences, University of Pavia, Pavia, 11University of Pavia, Department of Surgical, Clinical, Paediatric and Diagnostic Science, General Surgery 1, IRCCS Fondazione Policlinico San Matteo, Pavia, ItalyAbstract: In the last two decades, animal models have become important tools in understanding and treating pain, and in predicting analgesic efficacy. Although rodent models retain a dominant role in the study of pain mechanisms, large animal models may predict human biology and pharmacology in certain pain conditions more accurately. Taking into consideration the anatomical and physiological characteristics common to man and pigs (median body size, digestive apparatus, number, size, distribution and communication of vessels in dermal skin, epidermal–dermal junctions, the immunoreactivity of peptide nerve fibers, distribution of nociceptive and non-nociceptive fiber classes, and changes in axonal excitability), swines seem to provide the most suitable animal model for pain assessment. Locomotor function, clinical signs, and measurements (respiratory rate, heart rate, blood pressure, temperature, electromyography), behavior (bright/quiet, alert, responsive, depressed, unresponsive), plasma concentration of substance P and cortisol, vocalization, lameness, and axon reflex vasodilatation by laser Doppler imaging have been used to assess pain, but none of these evaluations have proved entirely satisfactory. It is necessary to identify new methods for evaluating pain in large animals (particularly pigs), because of their similarities to humans. This could lead to improved assessment of pain and improved analgesic treatment for both humans and laboratory animals.Keywords: pain assessment, experimental model, translational research
- Published
- 2014
27. Genetics and opioids: Towards more appropriate prescription in cancer pain
- Author
-
Bugada, D, Lorini, L, Fumagalli, R, Allegri, M, Lorini, F, Bugada D., Lorini L. F., Fumagalli R., Allegri M., LORINI, FERDINANDO LUCA, Bugada, D, Lorini, L, Fumagalli, R, Allegri, M, Lorini, F, Bugada D., Lorini L. F., Fumagalli R., Allegri M., and LORINI, FERDINANDO LUCA
- Abstract
Opioids are extensively used in patients with cancer pain; despite their efficacy, several patients can experience ineffective analgesia and/or side effects. Pharmacogenetics is a new approach to drug prescription based on the “personalized-medicine” concept, i.e., the ability of tailoring treatments to each individual’s genetic/genomic profile. Pharmacogenetics aims to identify specific genetic variants that influence pharmacokinetics and pharmacodynamics of drugs, better determining their effectiveness/safety profile. Opioid response is a complex scenario, but some gene variants have shown a correlation with pain sensitivity, as well as with opioid metabolism and clinical efficacy/adverse events. Although questions remain unanswered, some of these gene variants may already be used to identify specific patients’ phenotypes that are more prone to experience better clinical response (i.e., better analgesia and/or less adverse events). Once adopted, this approach to opioid prescription may improve a patient’s outcome. This review summarizes the available data on genetic variants and opioid response: we will focus on basic pharmacogenetic and its impact in the clinical scenario discussing how they may lead to more appropriate opioid prescription in cancer patients.
- Published
- 2020
28. The Lancet Global Health Commission on financing primary health care: putting people at the centre.
- Author
-
Hanson, K, Brikci, N, Erlangga, D, Alebachew, A, De Allegri, M, Balabanova, D, Blecher, M, Cashin, C, Esperato, A, Hipgrave, D, Kalisa, I, Kurowski, C, Meng, Q, Morgan, D, Mtei, G, Nolte, E, Onoka, C, Powell-Jackson, T, Roland, M, Sadanandan, R, Stenberg, K, Vega Morales, J, Wang, H, Wurie, H, Hanson, K, Brikci, N, Erlangga, D, Alebachew, A, De Allegri, M, Balabanova, D, Blecher, M, Cashin, C, Esperato, A, Hipgrave, D, Kalisa, I, Kurowski, C, Meng, Q, Morgan, D, Mtei, G, Nolte, E, Onoka, C, Powell-Jackson, T, Roland, M, Sadanandan, R, Stenberg, K, Vega Morales, J, Wang, H, and Wurie, H
- Published
- 2022
29. Consequences of the 118A>G polymorphism in the OPRM1 gene: translation from bench to bedside?
- Author
-
Mura E, Govoni S, Racchi M, Carossa V, Ranzani GN, Allegri M, and van Schaik RHN
- Subjects
Medicine (General) ,R5-920 - Abstract
Elisa Mura,1 Stefano Govoni,1 Marco Racchi,1 Valeria Carossa,1 Guglielmina Nadia Ranzani,2 Massimo Allegri,3,4 Ron HN van Schaik5 1Department of Drug Sciences, Centre of Excellence in Applied Biology, University of Pavia, Pavia, Italy; 2Department of Biology and Biotechnology, University of Pavia, Pavia, Italy; 3Pain Therapy Service, Foundation IRCCS San Matteo Hospital, Pavia, Italy; 4Department of Clinical, Surgical Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy; 5Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, The Netherlands Abstract: The 118A>G single nucleotide polymorphism (SNP) in the µ-opioid receptor (OPRM1) gene has been the most described variant in pharmacogenetic studies regarding opioid drugs. Despite evidence for an altered biological function encoded by this variant, this knowledge is not yet utilized clinically. The aim of the present review was to collect and discuss the available information on the 118A>G SNP in the OPRM1 gene, at the molecular level and in its clinical manifestations. In vitro biochemical and molecular assays have shown that the variant receptor has higher binding affinity for ß-endorphins, that it has altered signal transduction cascade, and that it has a lower expression compared with wild-type OPRM1. Studies using animal models for 118A>G have revealed a double effect of the variant receptor, with an apparent gain of function with respect to the response to endogenous opioids but a loss of function with exogenous administered opioid drugs. Although patients with this variant have shown a lower pain threshold and a higher drug consumption in order to achieve the analgesic effect, clinical experiences have demonstrated that patients carrying the variant allele are not affected by the increased opioid consumption in terms of side effects. Keywords: µ-opioid receptor, opioids, pharmacogenetics, pain, analgesia
- Published
- 2013
30. PROGRAMMING CHARACTERISTICS OF SPINAL CORD STIMULATION FOR FAILED-BACK SURGERY SYNDROME AND NON-OPERATED SPINAL STENOSIS: PROSPECTIVE ANALYSIS OF 72 PATIENTS: WIP16–0499
- Author
-
Manchiaro, P., Baciarello, M., Valente, A., Allegri, M., Marchesini, M., and Fanelli, G.
- Published
- 2016
31. SPINAL CORD STIMULATION IN NONOPERATED SPINAL STENOSIS COMPARED TO PERSISTENT PAIN AFTER SPINE SURGERY: A PROSPECTIVE ANALYSIS OF 199 CASES: WIP16–0453
- Author
-
Manchiaro, P., Baciarello, M., Salici, F., Marchesini, M., Allegri, M., and Fanelli, G.
- Published
- 2016
32. GENETICS AND GENOMICS TO PREDICT LOW BACK PAIN: WHICH ARE THE NEW FRONTIERS?: WIP16–0551
- Author
-
Allegri, M., De Gregori, M., Marchesini, M., Baciarello, M., Montella, S., Compagnone, C., and Fanelli, G.
- Published
- 2016
33. Multicentre multinational trial comparing coronally advanced rotated papillae flaps with connective tissue graft or collagen construct for coverage of multiple adjacent recessions: RCI56
- Author
-
Tonetti, M., Cortellini, P., Pellegrini, G., Nieri, M., Bonaccini, D., Allegri, M., Bouchard, P., Cairo, F., Conforti, G., Fourmousis, Y., Graziani, F., Guerrero, A., Halben, J., Rasperini, G., Topoll, H., Wachtel, H., Wallkamm, B., Zabalegui, I., and Zuhr, O.
- Published
- 2015
34. The pharmacological treatment of neuropathic pain
- Author
-
Bonezzi, C., Allegri, M., Demartini, L., and Buonocore, M.
- Published
- 2009
- Full Text
- View/download PDF
35. Analysis of a population of patients who were referred to a second level pain center: Clinical and demographic characteristics
- Author
-
Bonezzi, C., Pitino, E., and Allegri, M.
- Published
- 2009
- Full Text
- View/download PDF
36. Electrical Nerve Stimulation and Percutaneous Identification of the Target
- Author
-
Perotti, L., primary, Allegri, M., additional, Matteazzi, A., additional, and Grossi, P., additional
- Published
- 2013
- Full Text
- View/download PDF
37. L'efficience des politiques d'exemption du paiement des soins de santé maternelle au Burkina Faso
- Author
-
Nguyen, H.T., Torbica, A., Brenner, S, Kiendrébéogo, J.A., Tapsoba, L., Ridde, Valéry, De Allegri, M., Centre population et développement (CEPED - UMR_D 196), Institut de Recherche pour le Développement (IRD)-Université de Paris (UP), Ridde, Valéry (ed.), and Mbow Sane, N. B. (préf.)
- Subjects
[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,BURKINA FASO ,[SDV.MHEP.GEO]Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetrics ,[SHS.ECO]Humanities and Social Sciences/Economics and Finance - Abstract
La réduction et la suppression du paiement direct pour les services de soins essentiels sont récemment devenues un instrument clé pour faire progresser la couverture santé universelle en Afrique subsaharienne, mais il n'existe pas de preuves de leur efficience. Nous avons cherché à combler cette lacune en estimant l'efficience de deux interventions d'exemption du paiement direct au Burkina Faso entre 2007 et 2015 : la politique nationale de réduction de 80/100 du paiement direct pour les services de soins de santé et le projet pilote de suppression complète (100/100) du paiement direct pour les soins de santé dans la région du Sahel. Par rapport à la base de référence, la politique nationale de réduction de 80/100 du paiement direct et le projet pilote de suppression du paiement direct ont tous deux étés très rentables : les ratios coût-efficacité différentiels (ICER) sont de 210,22 USD et de 252,51 USD par année de vie ajustée sur l'incapacité (AVCI). Par rapport à la politique nationale de réduction de 80/100des paiements directs, le projet pilote de suppression du paiement direct implique un rapport coût-efficacité différentiel de 309,74 USD par AVCI évitée. Notre étude suggère qu'il est intéressant et efficient pour le Burkina Faso de passer d'une réduction de 80/100 à la suppression complète du paiement direct pour les soins d'accouchement.
- Published
- 2021
38. Le financement basé sur la performance et les ruptures de stocks de médicaments essentiels au Cameroun
- Author
-
Sieleunou, I., De Allegri, M., Enok Bonong, P.R., Ouédraogo, S., Ridde, Valéry, Centre population et développement (CEPED - UMR_D 196), Institut de Recherche pour le Développement (IRD)-Université de Paris (UP), Ridde, Valéry (ed.), and Mbow Sane, N. B. (préf.)
- Subjects
CAMEROUN ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,[SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences ,[SHS.ECO]Humanities and Social Sciences/Economics and Finance - Abstract
En 2011, le gouvernement du Cameroun a lancé son programme de financement basé sur la performance (FBP). Notre étude a examiné les effets de l'intervention du FBP sur la disponibilité des médicaments essentiels à l'aide des données d'un essai contrôlé randomisé (ECR) réalisé avec 205 formations sanitaires de trois régions (Est, Nord-Ouest, Sud-Ouest). La disponibilité de plusieurs groupes de médicaments essentiels a été définie en évaluant les ruptures de stock au cours des 30 jours précédant la collecte des données de l'ECR. Nos estimations suggèrent que l'intervention du FBP n'a eu aucun effet sur les ruptures de stocks de médicaments pour les soins prénataux, de vaccins, de médicaments pour la prise en charge intégrée des maladies de l'enfance et de médicaments pour le travail et l'accouchement. Toutefois, l'intervention a été associée à une réduction significative de 34% des ruptures de stock de médicaments de planification familiale. Ces résultats mitigés étaient probablement la conséquence d'un échec partiel de la mise en oeuvre, allant de la perturbation et de l'interruption des services à une autonomie limitée des formations sanitaires dans la prise des décisions et à un retard considérable dans le paiement des prestations.
- Published
- 2021
39. Replication of fifteen loci involved in human plasma protein N-glycosylation in 4,802 samples from four cohorts
- Author
-
Sharapov, S.Z., Shadrina, A.S., Tsepilov, Y.A., Elgaeva, E.E., Tiys, E.S., Feoktistova, S.G., Zaytseva, O.O., Vučković, F., Cuadrat, R., Jäger, S., Wittenbecher, C., Karssen, L.C., Timofeeva, M., Tillin, T., Trbojević-Akmačić, I., Štambuk, T., Rudman, N., Krištić, J., Šimunović, J., Momčilović, A., Vilaj, M., Jurić, J., Slana, A., Gudelj, I., Klarić, T., Puljak, L., Skelin, A., Kadić, A.J., Van Zundert, J., Chaturvedi, N., Campbell, H., Dunlop, M., Farrington, S.M., Doherty, M., Dagostino, C., Gieger, C., Allegri, M., Williams, F., Schulze, M.B., Lauc, G., and Aulchenko, Y.S.
- Subjects
Genetic Association Study ,Glycosylation ,Locus ,Replication ,Total Plasma N-glycome - Abstract
Human protein glycosylation is a complex process, and its in vivo regulation is poorly understood. Changes in glycosylation patterns are associated with many human diseases and conditions. Understanding the biological determinants of protein glycome provides a basis for future diagnostic and therapeutic applications. Genome-wide association studies (GWAS) allow to study biology via a hypothesis-free search of loci and genetic variants associated with a trait of interest. Sixteen loci were identified by three previous GWAS of human plasma proteome N-glycosylation. However, the possibility that some of these loci are false positives needs to be eliminated by replication studies, which have been limited so far. Here, we use the largest set of samples so far (4,802 individuals) to replicate the previously identified loci. For all but one locus, the expected replication power exceeded 95%. Of the sixteen loci reported previously, fifteen were replicated in our study. For the remaining locus (near the KREMEN1 gene) the replication power was low, and hence replication results were inconclusive. The very high replication rate highlights the general robustness of the GWAS findings as well as the high standards adopted by the community that studies genetic regulation of protein glycosylation. The fifteen replicated loci present a good target for further functional studies. Among these, eight genes encode glycosyltransferases: MGAT5, B3GAT1, FUT8, FUT6, ST6GAL1, B4GALT1, ST3GAL4, and MGAT3. The remaining seven loci offer starting points for further functional follow-up investigation into molecules and mechanisms that regulate human protein N-glycosylation in vivo.
- Published
- 2021
40. L'évolution des inégalités de dépenses de santé au Burkina Faso
- Author
-
Rudasingwa, M., Yeboah, E., Bonnet, Emmanuel, Ridde, Valéry, Somé, P.A., De Allegri, M., Pôle de recherche pour l'organisation et la diffusion de l'information géographique (PRODIG (UMR_8586 / UMR_D_215 / UM_115)), Université Paris 1 Panthéon-Sorbonne (UP1)-Institut de Recherche pour le Développement (IRD)-AgroParisTech-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP), Centre population et développement (CEPED - UMR_D 196), Institut de Recherche pour le Développement (IRD)-Université de Paris (UP), Ridde, Valéry (ed.), and Mbow Sane, N. B. (préf.)
- Subjects
[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,BURKINA FASO ,[SHS.ECO]Humanities and Social Sciences/Economics and Finance - Abstract
Le Burkina Faso a mis en oeuvre différentes politiques afin d'accroître l'accès aux services de santé, en particulier pour les femmes et les enfants. Cette étude vise à évaluer si les investissements réalisés ont amélioré l'équité des dépenses de santé pour les différents groupes socio-économiques. Les résultats indiquent une diminution substantielle des inégalités dans les dépenses publiques et globales de santé au fil du temps, tant pour les services curatifs que pour les accouchements médicalisés. Toutefois, les inégalités de dépenses de santé sont encore en faveur des moins pauvres pour les dépenses globales et pour les dépenses dans les hôpitaux. Cela s'explique en grande partie à cause de la persistance des paiements directs élevés qui ne sont pas abordables pour les plus pauvres.
- Published
- 2021
41. L'impact de la réduction et de la suppression des paiements directs sur la prestation de services au Burkina Faso
- Author
-
Nguyen, H.T., Zombré, D., Ridde, Valéry, De Allegri, M., Centre population et développement (CEPED - UMR_D 196), Institut de Recherche pour le Développement (IRD)-Université de Paris (UP), Ridde, Valéry (ed.), and Mbow Sane, N. B. (préf.)
- Subjects
SAHEL ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,BURKINA FASO ,[SHS.ECO]Humanities and Social Sciences/Economics and Finance - Abstract
Les politiques de réduction et de suppression des frais d'utilisation ont fait l'objet de recherches approfondies, mais il existe peu de preuves rigoureuses de leurs effets durables en ce qui concerne l'utilisation des services de soins. De plus, aucune preuve n'existe sur les effets d'une réduction partielle par rapport à la suppression totale des frais d'utilisation. Notre étude s'est déroulée dans quatre districts de la région du Sahel au Burkina Faso, où la politique nationale de réduction des frais d'utilisation (SONU) lancée en 2007 (réduction de 80/100 des frais d'utilisation) coexistait avec un projet pilote de suppression des frais d'utilisation lancé en 2008. Les résultats montrent que la SONU a produit une augmentation cumulée de 31,4/100 sur huit ans dans les quatre districts étudiés. Le projet pilote a encore amélioré l'utilisation et a produit une augmentation supplémentaire de 23,2/100 sur six ans. Les politiques de réduction et de suppression des frais d'utilisation ne suffisent pas à elles seules pour obtenir une couverture complète. Il est donc nécessaire de mettre en oeuvre des mesures supplémentaires, ciblant par exemple les barrières géographiques et les lacunes en matière de connaissances, afin que toutes les femmes accouchent en présence d'une personne qualifiée.
- Published
- 2021
42. Les effets du financement basé sur les résultats au Mali sur le recours aux soins
- Author
-
Zombré, D., De Allegri, M., Ridde, Valéry, Centre population et développement (CEPED - UMR_D 196), Institut de Recherche pour le Développement (IRD)-Université de Paris (UP), Ridde, Valéry (ed.), and Mbow Sane, N. B. (préf.)
- Subjects
KOULIKORO ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,[SHS.ECO]Humanities and Social Sciences/Economics and Finance ,MALI - Abstract
Le financement basé sur la performance (FBR) est de plus en plus mis en oeuvre dans les pays à faible et moyen revenu afin d'accroître l'utilisation et la qualité des soins de santé primaires. Toutefois, les preuves de son impact sont mitigées et varient considérablement d'un contexte à l'autre. Nous avons examiné les effets de la mise en oeuvre puis du retrait du programme pilote de FBR dans la région de Koulikoro au Mali sur une série d'indicateurs pertinents de santé maternelle et infantile. L'étude montre que ni l'introduction ni le retrait du programme pilote de FBR n'a eu un impact significatif sur la tendance des indicateurs d'utilisation des services de santé maternelle et infantile. L'absence d'effets significatifs pourrait s'expliquer par les faiblesses dans la conception de l'intervention et par le contexte de sa mise en oeuvre.
- Published
- 2021
43. Il diritto all’oblio del soggetto minore nel Regolamento europeo sulla protezione dei dati personali
- Author
-
Allegri, M. R.
- Subjects
Oblio ,Consenso ,Minori ,Minori, GDPR, Oblio, Consenso ,GDPR - Published
- 2021
44. La diffusion politique du financement basé sur les résultats au Mali
- Author
-
Gautier, L., Coulibaly, A., De Allegri, M., Ridde, Valéry, Centre population et développement (CEPED - UMR_D 196), Institut de Recherche pour le Développement (IRD)-Université de Paris (UP), Ridde, Valéry (ed.), and Mbow Sane, N. B. (préf.)
- Subjects
KOULIKORO ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,[SHS.ECO]Humanities and Social Sciences/Economics and Finance ,[SHS.SCIPO]Humanities and Social Sciences/Political science ,MALI ,BAMAKO - Abstract
Depuis 2009, le Mali s'est lancé dans une réflexion sur l'adoption du financement basé sur les résultats (FBR) afin d'améliorer l'utilisation et la qualité des services de santé maternelle et infantile. De nombreux acteurs étrangers d'Europe et d'Afrique ont contribué à diffuser l'idée et les principes du FBR auprès des acteurs et actrices malien-ne-s du niveau central et de tous les niveaux de la décentralisation sanitaire. Les interactions sociales entre les entrepreneurs et entrepreneuses de la diffusion et les acteurs et actrices clés du processus politique se sont avérées déterminantes pour la diffusion du FBR. Non seulement les intermédiaires se sont "approprié-e-s" le processus de diffusion, mais ce processus leur a permis de devenir des expert-e-s étrangers et étrangères diffusant la politique dans d'autres pays.
- Published
- 2021
45. Les dépenses excessives de santé des indigent-e-s après l'arrêt du FBR au Burkina Faso
- Author
-
Beaugé, Y., Ridde, Valéry, Bonnet, Emmanuel, Souleymane, S., Kuunibe, N., De Allegri, M., Centre population et développement (CEPED - UMR_D 196), Institut de Recherche pour le Développement (IRD)-Université de Paris (UP), Pôle de recherche pour l'organisation et la diffusion de l'information géographique (PRODIG (UMR_8586 / UMR_D_215 / UM_115)), Université Paris 1 Panthéon-Sorbonne (UP1)-Institut de Recherche pour le Développement (IRD)-AgroParisTech-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP), Ridde, Valéry (ed.), and Mbow Sane, N. B. (préf.)
- Subjects
[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,BURKINA FASO ,[SHS.ECO]Humanities and Social Sciences/Economics and Finance - Abstract
Mesurer les progrès réalisés vers la protection contre les risques financiers pour les plus pauvres est essentiel dans le cadre de la couverture sanitaire universelle. L'étude a évalué le niveau des dépenses directes et les facteurs associés à des dépenses directes de santé excessives pour les indigent-e-s qui avaient été ciblé-e-s et exempté-e-s dans le cadre du financement basé sur la performance au Burkina Faso. Les résultats montrent que 83,64/100 des personnes interrogées affirment disposer d'une carte d'exemption du paiement. Les indigent-e-s affirment avoir dépensé en moyenne 23051,62 FCFA (39,18 USD) pour recevoir des services de santé dans des formations sanitaires publiques alors qu'ils étaient censés être gratuits. De plus, la probabilité d'engager des dépenses excessives était associée de manière négative au fait d'être une femme et d'avoir une carte d'exemption.
- Published
- 2021
46. Dolore cronico: il ruolo dell’anestesia loco-regionale eco-guidata
- Author
-
Bugada, D., Minella, C. E., and Allegri, M.
- Published
- 2012
- Full Text
- View/download PDF
47. Power System Topology for EV Parks
- Author
-
Parise, G., primary, Parise, L., additional, Allegri, M., additional, Mazzaro, M., additional, Pennacchia, R., additional, Regoli, F., additional, and Marra, V., additional
- Published
- 2021
- Full Text
- View/download PDF
48. Estimating the distributional incidence of healthcare spending on maternal health services in Sub-Saharan Africa : benefit incidence analysis in Burkina Faso, Malawi, and Zambia
- Author
-
Rudasingwa, M., Yeboah, E., De Allegri, M., Bonnet, Emmanuel, Ridde, Valéry, Somé, P.A., Muula, A., Chitah, B.M., Mphuka, C., Unité mixte internationale Résiliences (UMI RESILIENCES), Centre ivoirien de recherches économiques et sociales (CIRES)-Université de Cocody, Centre population et développement (CEPED - UMR_D 196), Institut de Recherche pour le Développement (IRD)-Université de Paris (UP), and Institut de Recherche pour le Développement (IRD)-Université Paris Cité (UPC)
- Subjects
[SDV.EE]Life Sciences [q-bio]/Ecology, environment ,ZAMBIE ,[QFIN]Quantitative Finance [q-fin] ,MALAWI ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,BURKINA FASO ,[SHS.ANTHRO-SE]Humanities and Social Sciences/Social Anthropology and ethnology - Abstract
Improving access to maternal health services is a critical policy concern, especially in Sub- Saharan Africa (SSA) where maternal mortality rates remain very high, particularly so among the poorest segments of society. Hence, following the global call to reduce maternal mortality embedded in the Sustainable Development Goal 3, multiple interventions have been designed and implemented across SSA countries to foster progress towards Universal Health Coverage (UHC) of maternal health services, including skilled birth attendance. While evidence on the impact of these interventions on access to service use is increasing, evidence on the distributional incidence of the financial investment they entail is still limited. This paper aims to close this gap in knowledge by conducting a quasi-longitudinal benefit incidence analysis to assess equality of both public and overall health spending on maternal health services in three Sub-Saharan African countries: Burkina Faso, Malawi and Zambia. The study relied on healthcare utilization data derived from different nationallevel household surveys (including Demographic and Health Survey, Performance based Financing Survey, and Zambia Household Health and Expenditure Survey) and health expenditure data derived from National Health Accounts. The findings demonstrate increasing equality in health spending over time, but also considerable persistent heterogeneity in distributional incidence across provinces/regions/districts. These findings suggest that the implementation of UHC-specific reforms targeting maternal care was effective in increasing equality in health spending, meaning that more financial resources reached the poorest segments of society, but was not yet sufficient to remove differences across provinces/regions/districts. Further research is needed to investigate sources of regional disparities and identify strategies to overcome them.
- Published
- 2020
49. No effects of pilot performance-based intervention implementation and withdrawal on the coverage of maternal and child health services in the Koulikoro region, Mali : an interrupted time series analysis
- Author
-
Zombré, D., De Allegri, M., and Ridde, Valéry
- Subjects
health services coverage ,evaluation ,Performance-based financing ,interrupted time series ,Mali ,policy - Abstract
Performance-based financing (PBF) has been promoted and increasingly implemented across low- and middle-income countries to increase the utilization and quality of primary health care. However, the evidence of the impact of PBF is mixed and varies substantially across settings. Thus, further rigorous investigation is needed to be able to draw broader conclusions about the effects of this health financing reform. We examined the effects of the implementation and subsequent withdrawal of the PBF pilot programme in the Koulikoro region of Mali on a range of relevant maternal and child health indicators targeted by the programme. We relied on a control interrupted time series design to examine the trend in maternal and child health service utilization rates prior to the PBF intervention, during its implementation and after its withdrawal in 26 intervention health centres. The results for these 26 intervention centres were compared with those for 95 control health centres, with an observation window that covered 27 quarters. Using a mixed-effects negative binomial model combined with a linear spline regression model and covariates adjustment, we found that neither the introduction nor the withdrawal of the pilot PBF programme bore a significant impact in the trend of maternal and child health service use indicators in the Koulikoro region of Mali. The absence of significant effects in the health facilities could be explained by the context, by the weaknesses in the intervention design and by the causal hypothesis and implementation. Further inquiry is required in order to provide policymakers and practitioners with vital information about the lack of effects detected by our quantitative analysis.yy
- Published
- 2020
50. The association between genome-wide polymorphisms and chronic postoperative pain: a prospective observational study
- Author
-
van Reij, R. R., Hoofwijk, D. M. N., Rutten, B. P. F., Weinhold, L., Leber, M., Joosten, E. A. J., Ramirez, A., van den Hoogen, N. J., Allegri, M., Bassoricci, E., Bettinelli, S., Bugada, D., Cedrati, V. L. E., Cappelleri, G., Compagnone, C., De Gregori, M., Fumagalli, R., Grimaldi, S., Mantelli, M., Molinaro, M., Zorzetto, M., Anesthesiologie, RS: MHeNs - R3 - Neuroscience, MUMC+: MA Psychiatrie (3), Psychiatrie & Neuropsychologie, and MUMC+: MA Anesthesiologie (9)
- Subjects
EXPRESSION ,medicine.medical_specialty ,GENES ,SURGERY ,medicine.medical_treatment ,LOCI ,Genome-wide association study ,Polymorphism, Single Nucleotide ,Quality of life ,Internal medicine ,IMPUTATION ,Medicine ,Humans ,risk factors ,Prospective Studies ,CHRONIC POSTSURGICAL PAIN ,Genetic association ,Aged ,genome‐wide association study ,Pain, Postoperative ,Hysterectomy ,genome-wide association study ,business.industry ,Chronic pain ,Articles ,Middle Aged ,medicine.disease ,NERVOUS-SYSTEM ,Advances in Peri‐operative Care ,PREVALENCE ,Anesthesiology and Pain Medicine ,DISEASES ,Cohort ,RISK-FACTORS ,Observational study ,Female ,Original Article ,business ,chronic pain ,Abdominal surgery ,Follow-Up Studies - Abstract
Summary Chronic postoperative pain is common and can have a negative impact on quality of life. Recent studies show that genetic risk factors are likely to play a role, although only gene‐targeted analysis has been used to date. This is the first genome‐wide association study to identify single‐nucleotide polymorphisms associated with the development of chronic postoperative pain based on two independent cohorts. In a discovery cohort, 330 women scheduled for hysterectomy were genotyped. A case–control association analysis compared patients without chronic postoperative pain and the 34 who had severe chronic postoperative pain 3 months after surgery. No single‐nucleotide polymorphisms reached genome‐wide significance, but several showed suggestive associations with chronic postoperative pain (p
- Published
- 2020
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.